Viewing Study NCT00237393


Ignite Creation Date: 2025-12-25 @ 1:10 AM
Ignite Modification Date: 2025-12-25 @ 11:21 PM
Study NCT ID: NCT00237393
Status: COMPLETED
Last Update Posted: 2008-02-21
First Post: 2005-10-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
Sponsor: Ralph H. Johnson VA Medical Center
Organization:

Study Overview

Official Title: A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD
Status: COMPLETED
Status Verified Date: 2005-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PTSD
Brief Summary: The purpose of the study is to determine if quetiapine is effective in the treatment of PTSD.
Detailed Description: Objective: To assess the impact of quetiapine on core PTSD symptoms and associated psychiatric comorbidity including depressive and positive and negative psychotic symptoms.

Research Design: 12-week, double-blind, placebo-controlled, randomized, fixed-flexible dose trial of quetiapine monotherapy.

Intervention: Eligible patients will be randomized to receive quetiapine starting at 25 mg daily or matching placebo. Dose adjustments (to a minimum of 50 mg or a maximum of 800 mg), will be made at the investigator's discretion and according to patient's clinical response.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
HR-10762 None None View